Pilot Investigation on Markers of Bone Metabolism, Angiogenesis, and Neuroendocrine Activity as Potential Predictors of Survival of Metastatic Prostate Cancer Patients with Bone Metastases
Ortiz, M. Àngels (Institut de Recerca Sant Pau)
Anguera, Georgia (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Cantó, Elisabet (Institut de Recerca Sant Pau)
Alejandre, Jose (Institut de Recerca Sant Pau)
Mora, Josefina (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Osuna Gómez, Rubén (Institut de Recerca Sant Pau)
Mulet Gual, Maria (Institut de Recerca Sant Pau)
Mora, Pradip (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Antonijuan, Assumpta (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Sánchez, Sofia (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Ramírez, Ona (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Orantes, Vanessa (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Maroto Rey, Pablo (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Vidal, Silvia (Institut de Recerca Sant Pau)

Date:	2025
Abstract:	Prostate cancer with bone metastasis exhibits significant heterogeneity, complicating prognosis, and treatment. This study explores the potential of plasma, serum, and urine biomarkers to stratify patients and evaluate their prognostic value. Using two-step clustering, we analyzed baseline levels of Platelet-derived growth factor-BB (PDGF-BB), Insulin-like growth factor-binding protein 1 (IGFBP-1), Bone Morphogenetic Protein 2 (BMP-2), Vascular endothelial growth factor (VEGF) (plasma and urine), prostate-specific antigen (PSA), neuron-specific enolase (NSE), chromogranin A (CgA) and bone-specific alkaline phosphatase (BAP) (serum) and creatinine (Cr), and type I collagen-cross-linked N telopeptide (NTx) (urine) in 29 patients with prostate cancer and bone metastasis. Longitudinal biomarker dynamics were assessed at baseline, 6 months, and 12 months. Clinical outcomes were evaluated using Kaplan-Meier and multivariate analyses. Three distinct groups (C1, C2, and C3) were identified. C1 exhibited elevated pPDGF-BB and pVEGF levels, C3 had increased pBAP and uNTx/Cr, and C2 showed lower biomarker levels. Prior treatments influenced biomarker levels, with bisphosphonates reducing bone turnover markers and radiotherapy correlating with long-term changes in growth factors. Longitudinal analysis revealed unique biomarker dynamics within each group, with a tendency for pPDGF-BB and pVEGF levels to decrease over time in C1, and distinct trends in uNTx/Cr between groups. Despite individual biomarkers failing to predict survival, C3 patients demonstrated significantly worse survival than C1 and C2. Molecular clustering of peripheral blood and urinary biomarkers identifies distinct subgroups with metastatic castration-resistant prostate cancer patients outperforming traditional models in outcome prediction and supporting its potential for personalized treatment and prognosis.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Biomarkers ; Prostate cancer ; Bone metastasis
Published in:	International journal of molecular sciences, Vol. 26 Núm. 10 (May 2025) , ISSN 1422-0067

DOI: 10.3390/ijms26104669
PMID: 40429810

15 p, 1.8 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles